3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
12
Non-Muscle Invasive Bladder Neoplasms
9
Carcinoma, Transitional Cell
7
Stomach Neoplasms
4
Anus Neoplasms
4
Pancreatic Neoplasms
3
Carcinoma, Hepatocellular
3
Peritoneal Neoplasms
2
Liver Neoplasms
2
Colorectal Neoplasms
2
Appendiceal Neoplasms
2
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Pseudomyxoma Peritonei
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Recurrence, Local
1
Neoplasm Metastasis
1
Mycobacterium Infections
1
Gastrointestinal Neoplasms
1
Dermatitis
1
Carcinoma in Situ
1
Carcinoma
1
Anal Canal Carcinoma
1
Adenocarcinoma
1
Interventions
Gemcitabine
4
130-nm albumin-bound paclitaxel
4
pembrolizumab
3
napabucasin
3
Paclitaxel
3
Irinotecan
3
selpercatinib
2
pralsetinib
2
patritumab
2
Standard of Care
2
Pemetrexed
2
Nivolumab
2
Fluorouracil
2
Cyclophosphamide
2
Cisplatin
2
Carboplatin
2
Ascorbic Acid
2
Albumin-Bound Paclitaxel
2
valrubicin
1
sotorasib
1
ribociclib
1
relatlimab
1
pamiparib
1
osimertinib
1
ipatasertib
1
durvalumab
1
dostarlimab
1
cobimetinib
1
atezolizumab
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Neoplasms by Site
×
Mitomycin
×
Clear all
NCT01200992
2017-08-24
EMBARC-RF
Bioniche Life Sciences Inc.
Phase 3
Terminated
84 enrolled
7 charts